Placental growth factor (PlGF) enhances breast cancer cell motility by mobilising ERK1/2 phosphorylation and cytoskeletal rearrangement

British Journal of Cancer

Volumn 103, Issue 1, 2010, Pages 82-89

  Taylor, A P ^a   Leon, E ^a   Goldenberg, D M ^a  

^a CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

Author keywords

BP 1 peptide; breast cancer; Flt 1; IF protein; motility; PlGF

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; ACTIN; INTERMEDIATE FILAMENT PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PEPTIDE BP 1; PLACENTAL GROWTH FACTOR; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1; VIMENTIN; FLT1 PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PLACENTA PROTEIN;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL MIGRATION; CELL MOTILITY; CONTROLLED STUDY; CYTOSKELETON; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING; PRIORITY JOURNAL; PROTEIN STABILITY; PROTEIN SYNTHESIS; BREAST TUMOR; CELL MOTION; CHEMISTRY; DRUG EFFECT; FEMALE; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ACTINS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CYTOSKELETON; FEMALE; HUMANS; INTERMEDIATE FILAMENT PROTEINS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHORYLATION; PREGNANCY PROTEINS; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VIMENTIN;

EID: 77954176110     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605746     Document Type: Article

References (59)

1. Arthur WT, Burridge K (2001) RhoA inactivation by p190RhoGAP regulates cell spreading and migration by promoting membrane protrusion and polarity. Mol Biol Cell 12: 2711-2720
2. Bachelder RE, Wendt MA, Mercurio AM (2002) Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. Cancer Res 62: 7203-7206
3. Barros JC, Marshall CJ (2005) Activation of either ERK1/2 or ERK MAP kinase pathways can lead to disruption of the actin cytoskeleton. J Cell Sci 118: 1663-1671
4. Boecker W, Moll R, Dervan P, Buerger H, Poremba C, Diallo RI, Herbst H, Schmidt A, Lerch MM, Buchwalow IB (2002) Usual ductal hyperplasia of the breast is a committed stem (progenitor) cell lesion distinct from atypical ductal hyperplasia and ductal carcinoma in situ. J Pathol 198: 458-467
5. Brotherick I, Robson CN, Browell DA, Shenfine J, White MD, Cunliffe WJ, Shenton BK, Egan M, Webb LA, Lunt LG, Young JR, Higgs MJ (1998) Cytokeratin expression in breast cancer: phenotypic changes associated with disease progression. Cytometry 32: 301-308
6. Buhler H, Schaller G (2005) Transfection of keratin 18 gene in human breast cancer cells causes induction of adhesion proteins and dramatic regression of malignancy in vitro and in vivo. Mol Cancer Res 3: 365-371
7. Casalou C, Fragoso R, Nunes JF, Dias S (2007) VEGF/PlGF induces leukemia cell migration via P38/ERK1/2 kinase pathway, resulting in Rho GTPases activation and caveolae formation. Leukemia 21: 590-1594
8. Chan AY, Raft S, Bailly M, Wyckoff JB, Segall JE, Condeelis JS (1998) EGF stimulates an increase in actin nucleation and filament number at the leading edge of the lamellipod in mammary adenocarcinoma cells. J Cell Sci 111: 199-211
9. Chen CN, Hsieh FJ, Cheng YM, Cheng WF, Su YN, Chang KJ, Lee PH (2004) The significance of placenta growth factor in angiogenesis and clinical outcome of human gastric cancer. Cancer Lett 213: 73-82
10. Chen L, Necela BM, Su W, Yanagisawa M, Anastasiadis PZ, Fields AP, Thompson EA (2006) Peroxisome proliferator-activated receptor g promotes epithelial to mesenchymal transformation by rho GTPase-dependent activation of ERK1/2. J Biol Chem 281: 24575-24587
11. Chu YW, Seftor EA, Romer LH, Hendrix MJ (1996) Experimental coexpression of vimentin and keratin intermediate filaments in human melanoma cells augments motility. Am J Pathol 148: 63-69
12. DePrimo SE, Bello CL, Smeraglia J, Baum CM, Spinella D, Rini BI, Michaelson MD, Motzer RJ (2007) Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med 5: 32-42
13. Domagala W, Lasota J, Bartkowiak J, Weber K, Osborn M (1990) Vimentin is preferentially expressed in human breast carcinomas with low estrogen receptor and high Ki-67 growth fraction. Am J Pathol 136: 219-227
14. Eckes B, Dogic D, Colucci-Guyon E, Wang N, Maniotis A, Ingber D, Merckling A, Langa F, Aumailley M, Delouvee A, Koteliansky V, Babinet C, Krieg T (1998) Impaired mechanical stability, migration and contractile capacity in vimentin-deficient fibroblasts. J Cell Sci 111: 1897-1907
15. Escudero-Esparza A, Martin TA, Douglas-Jones A, Mansel RE, Jiang WG (2010) PGF isoforms, PlGF-1 and PGF-2, and the PGF receptor, neuropilin, in human breast cancer: prognostic significance. Oncol Rep 23: 537-544
16. Ferrero M, Spyratos F, Le Doussal V, Desplaces A, Rouesse J (1990) Flow cytometric analysis of DNA content and keratins by using CK7, CK8, CK18, CK19, and KL1 monoclonal antibodies in benign and malignant human breast tumors. Cytometry 11: 716-724
17. Fischer C, Jonckx B, Mazzone M, Zacchigna S, Loges S, Pattarini L, Chorianopoulos E, Liesenborghs L, Koch M, De Mol M, Autiero M, Wyns S, Plaisance S, Moons L, van Rooijen N, Giacca M, Stassen JM, Dewerchin M, Collen D, Carmeliet P (2007) Anti-PlGF inhibits growth of VEGFR-inhibitor-resistant tumors without affecting healthy vessels. Cell 131: 463-475
18. Fischer C, Mazzone M, Jonckx B, Carmeliet P (2008) Flt1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat Rev Cancer 8: 942-956
19. Harper L, Kashiwagi Y, Pusey CD, Hendry BM, Domin J (2007) Platelet-derived growth factor reorganizes the actin cytoskeleton through 3-phosphoinositide-dependent and 3-phosphoinositide-independent mechanisms in human mesangial cells. Nephron Physiol 107: 45-56
20. Hartig R, Shoeman RL, Janetzko A, Tolstonog G, Traub P (1998) DNA-mediated transport of the intermediate filament protein vimentin into the nucleus of cultured cells. J Cell Sci 111: 3573-3584
21. Helfand BT, Chang L, Goldman RD (2004) Intermediate filaments are dynamic and motile elements of cellular architecture. J Cell Sci 117: 133-141
22. Hendrix MJC, Seftor EA, Seftor REB, Trevor KT (1997) Experimental co-expression of vimentin and keratin intermediate filaments in human breast cancer cells results in phenotypic interconversion and increased invasive behavior. Am J Pathol 150: 483-495
23. Henson FMD, Vincent TA (2008) Alterations in the vimentin cytoskeleton in response to single impact load in an in vitro model of cartilage damage in the rat. BMC Musculoskel Disord 9: 94
24. Hirshman CA, Zhu D, Panettieri RA, Emala CW (2001) Actin depolymeri-zation via the b-adrenoceptor in airway smooth muscle cells. A novel PKA-independent pathway. Am J Physiol Cell Physiol 281: C1468-C1476
25. Hirshman CA, Zhu D, Pertel T, Panettieri RA, Emala CW (2005) Isoproterenol induces actin depolymerization in human airway smooth muscle cells via activation of an Src kinase and GS. Am J Physiol Lung Cell Mol Physiol 288: L924-L931
26. Ho M-C, Chen C-N, Lee H, Hsieh F-J, Shun C-T, Chang C-L, Lai Y-T, Lee P-H (2007) Placenta growth factor not vascular endothelial growth factor A or C can predict the early recurrence after radical resection of hepatocellular carcinoma. Cancer Lett 250: 237-249
27. Hu L, Lau SH, Tzang CH, Wen JM, Wang W, Xie D, Huang M, Wang Y, Wu MC, Huang JF, Zeng WF, Sham JS, Yang M, Guam XY (2004) Association of vimentin overexpression and hepatocellular carcinoma metastasis. Oncogene 23: 298-302
28. Ilic D, Furuta Y, Kanazawa S, Takeda N, Sobue K, Nakatsuji N, Nomura S, Fujimoto J, Okada M, Yamamoto T (1995) Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice. Nature 377: 539-544
29. Kagawa S, Matsuo A, Yagi Y, Ikematsu K, Tsuda R, Nakasono I (2009) The time-course analysis of gene expression during wound healing in mouse skin. Leg Med (Tokyo) 11: 70-75
30. Lee T-H, Seng S, Sekine M, Hinton C, Fu Y, Avraham HK, Avraham S (2007) Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1. PLoS Med 4: 1101-1116
31. Li B, Sharpe EE, Maupin AB, Teleron AA, Pyle AL, Carmeliet P, Young PP (2006) VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization. FASEB J 20: E664-E676
32. Liu Y, Poon RT, Li Q, Kok TW, Lau C, Fan ST (2005) Both antiangio-genesis-and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res 65: 3691-3699
33. Maes C, Coenegrachts L, Stockmans I, Daci E, Luttun A, Petryk A, Gopalakrishnan R, Moermans K, Smets N, Verfaillie CM, Carmeliet P, Bouillon R, Bouillon R, Carmeliet G (2006) Placental growth factor mediates mesenchymal cell development, cartilage turnover, and bone remodeling during fracture repair. J Clin Invest 116: 1230-1242
34. McInroy L, Maatta A (2007) Down-regulation of vimentin expression inhibits carcinoma cell migration and adhesion. Biochem Biophys Res Commun 360: 109-114
35. Mitra SK, Hanson DA, Schlaepfer DD (2005) Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol 6: 56-68, (review)
36. Oriolo AS, Wald FA, Ramsauer VP, Salas PJ (2007) Intermediate filaments: a role in epithelial polarity (review). Exp Cell Res (NIH Public Access) 313: 2255-2264
37. Papadopoulou MV, Bloomer WD, Taylor AP, Hernandez M, Blumenthal RD, Hollingshead MG (2007) Advantage of combining NLCQ-1 (NSC 709257) with radiation in treatment of human head and neck xenografts. Radiat Res 168: 65-71
38. Parr C, Watkins G, Boulton M, Cai J, Jiang WG (2005) Placenta growth factor is over-expressed and has prognostic value in human breast cancer. Eur J Cancer 41: 2819-2827
39. Pawlak G, Helfman DM (2002) MEK mediates v-Src-induced disruption of the actin cytoskeleton via inactivation of the Rho-ROCK-LIM kinase pathway. J Biol Chem 277: 26927-26933
40. Perlson E, Michaelevski I, Kowalsman N, Ben-Yaakov K, Shaked M, Seger R, Eisenstein M, Fainzilber M (2006) Vimentin binding to phosphorylated ERK sterically hinders enzymatic dephosphorylation of the kinase. J Mol Biol 264: 938-944
41. Ronnstrand L, Heldin CH (2001) Mechanisms of platelet-derived growth factor-induced chemotaxis. Int J Cancer 91: 757-762
42. Schlaepfer DD, Jones KC, Hunter T (1998) Multiple Grb2-mediated integrin-stimulated signaling pathways to ERK2/Mitogen-activated kinase: summation of both c-Src-and focal adhesion kinase-initiated tyrosine phosphorylation events. Mol Cell Biol 18: 2571-2585
43. Schoumacher M, Goldman RD, Louvard D, Vignjevic DM (2010) Actin, microtubules, and vimentin intermediate filaments cooperate for elongation of invadopodia. J Cell Biol 189: 541-556
44. Singh S, Sadacharan S, Su S, Belldegrun A, Persad S, Singh G (2003) Over-expression of vimentin: role in the invasive phenotype in an androgen-independent model of prostate cancer. Cancer Res 63: 2306-2311
45. Starzec A, Vassy R, Martin A, Lecouvey M, Di Benedetto M, Crepin M, Perret GY (2006) Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1. Life Sci 79: 2370-2381
46. Stathopoulou A, Vlachonikolis I, Mavroudis D, Perraki M, Kouroussis C, Apostoloki S, Malamos N, Kakolyris S, Kotsakis A, Xenidis N, Reppa D, Georgoulias V (2002) Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. J Clin Oncol 20: 3404-3412
47. Taylor AP, Osorio L, Craig R, Ying Z, Goldenberg DM, Blumenthal RD (2002) Tumor-specific regulation of angiogenic growth factors and their receptors during recovery from cytotoxic therapy. Clin Cancer Res 8: 1213-1222
48. Taylor AP, Rodriguez M, Adams K, Goldenberg DM, Blumenthal RD (2003) Altered tumor vessel maturation and proliferation in placenta growth factor-producing tumors: potential relationship to post-therapy tumor angiogenesis and recurrence. Int J Cancer 105: 158-164
49. Taylor AP, Goldenberg DM (2007) Role of placenta growth factor (PlGF) in malignancy, and evidence that an antagonistic PlGF/Flt-1 peptide inhibits the growth and metastasis of human breast cancer xenografts. Mol Cancer Ther 6: 524-531
50. Thomas PA, Kirschmann DA, Cerhan JR, Folberg R, Seftor EA, Sellers TA, Hendrix MJC (1999) Association between keratin and vimentin expression, malignant phenotype, and survival in postmenopausal breast cancer patients. Clin Cancer Res 5: 2698-2703
51. Tolstonog GV, Shoeman RL, Traub U, Traub P (2001) Role of the intermediate filament protein vimentin in delaying senescence and in the spontaneous immortalization of mouse embryo fibroblasts. DNA Cell Biol 20: 509-529
52. Tsuganezawa H, Sato S, Yamaji Y, Preisig PA, Moe OW, Alpern RJ (2002) Role of c-SRC and ERK in acid-induced activation of NHE3. Kidney Inter 62: 41-50
53. Wang D, Donner DB, Warren RS (2000) Homeostatic modulation of cell surface KDR and Flt1 expression and expression of the vascular endothelial cell growth factor (VEGF) receptor mRNAs by VEGF. J Biol Chem 275: 15905-15911
54. Wei SC, Tsao PN, Yu SC, Shun CT, Tsai-Wu JJ, Wu CH, Su YN, Hsieh FJ, Wong JM (2005) Placenta growth factor expression is correlated with survival of patients with colorectal cancer. Gut 54: 666-672
55. Willipinski-Stapelfeldt B, Riethdorf S, Assmann V, Woelfle U, Rau T, Sauter G, Heukeshoven J, Pantel K (2005) Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometa-static and primary breast carcinoma cells. Clin Cancer Res 11: 8006-8014
56. Wong C-H, Xia W, Lee NPY, Mruk DD, Lee WM, Cheng CY (2005) Regulation of ectoplasmic specialization dynamics in the seminiferous epithelium by focal adhesion-associated proteins in testosterone-suppressed rat testes. Endocrinology 146: 1192-1204
57. Yin G, Zheng Q, Yan C, Berk BC (2005) GIT1 is a scaffold for ERK1/2 activation in focal adhesions. J Biol Chem 280: 27705-27712
58. Yuan CC, Huang HC, Tsai LC, Ng HT, Huang TS (1997) Cytokeratin-19 associated with apoptosis and chemosensitivity in human cervical cancer cells. Apoptosis 2: 101-105
59. Zheng C-F, Guan K-L (1994) Cytoplasmic localization of the mitogen-activated protein kinase activator MEK. J Biol Chem 269: 19947-19952